Oxis Turbuhaler (Formoterol Fumarate Dihydrate)

Formoterol fumarate dihydrate, the active ingredient in Oxis Turbuhaler, is a long‑acting β2‑adrenergic agonist presented as a dry‑powder inhaler for inhalation use. It provides bronchodilation for maintenance therapy in asthma and chronic obstructive pulmonary disease in adults. GNH USA supplies Oxis Turbuhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Oxis Turbuhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Formoterol fumarate dihydrate is used in respiratory therapy targeting the bronchial smooth‑muscle pathway to improve airflow.

- Asthma: improves long‑term control and reduces symptoms when used with inhaled corticosteroids. - Chronic obstructive pulmonary disease (COPD): provides maintenance bronchodilation and helps reduce exacerbations. - Exercise‑induced bronchoconstriction: offers rapid onset relief of bronchospasm during physical activity.

Formoterol may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Tremor: mild shaking of the hands. - Headache: occasional mild to moderate headache. - Throat irritation: sensation of dryness or irritation in the throat. - Cough: transient cough after inhalation. - Palpitations: awareness of heart beating faster than usual. - Nervousness: mild feelings of anxiety or jitteriness.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing difficulty. - Cardiac arrhythmia: irregular heart rhythm that may require medical attention. - Hypokalemia: low blood potassium levels, potentially causing muscle weakness. - Severe allergic reaction: rash, swelling, or difficulty breathing indicating anaphylaxis.

When using Oxis Turbuhaler, patients and healthcare providers should consider several safety measures.

- Assess asthma or COPD severity: confirm that maintenance therapy with a long‑acting β2‑agonist is appropriate. - Review cardiovascular history: patients with arrhythmias or coronary disease need careful monitoring. - Monitor for paradoxical bronchospasm: discontinue if breathing worsens after inhalation. - Avoid abrupt discontinuation: tapering may be needed to prevent loss of bronchodilation. - Store at ambient temperature: keep below 25 °C, protect from moisture and direct sunlight.

Formoterol may interact with other medications that affect the cardiovascular or respiratory systems.

Major Interactions (Avoid): - Non‑selective β‑blockers: may reduce bronchodilator effect and precipitate bronchospasm. - Monoamine oxidase inhibitors (MAOIs): can increase risk of tachycardia and hypertension.

Moderate Interactions (Monitor Closely):\n- Diuretics: may potentiate hypokalemia, requiring electrolyte monitoring. - Theophylline: combined use can enhance cardiovascular stimulation. - Anticholinergic bronchodilators: additive bronchodilation may increase risk of tachycardia.